COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 182 participants.

Also called NCT05250596

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 182 participants (enrolled count) (from the registry)
Sponsor
Azienda USL Toscana Centro (from the registry)
Registry
  • NCT NCT05250596
  • EudraCT 2021-000637-13
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05250596. Randomized; no masking; primary purpose treatment. Start 2022-02-24 (actual); primary completion 2024-02-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
COLchicine On-admission to Reduce Inflammation in Acute Coronary Syndrome (COLOR-ACS)
Acronym
COLOR-ACS
Condition
Non ST Segment Elevation Acute Coronary Syndrome
Intervention (Drug)
Colchicine
Intervention (Drug)
Atorvastatin
Lead sponsor
Azienda USL Toscana Centro (class: other)

Record details

Record id
cardio:ct-nct05250596
Content hash
3dd405cb988cbba9b24b29610774315c920450ec86d82dd83f660a928e19e6d0